Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4434-4442

  Steinkamp, Mara P ^a   O'Mahony, Orla A ^a   Brogley, Michele ^a   Rehman, Haniya ^a   LaPensee, Elizabeth W ^a   Dhanasekaran, Saravana ^a   Hofer, Matthias D ^b   Kuefer, Rainer ^c   Chinnaiyan, Arul ^a   Rubin, Mark A ^d   Pienta, Kenneth J ^a   Robins, Diane M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; FLUTAMIDE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METASTASIS; MISSENSE MUTATION; MUTATION; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MOTIF; PROTEIN STABILITY;

AMINO ACID SUBSTITUTION; ANILIDES; ANTINEOPLASTIC AGENTS; AUTOPSY; CYCLOHEXIMIDE; DNA PRIMERS; FLUTAMIDE; HUMANS; LYMPHATIC METASTASIS; MALE; MUTATION; NITRILES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TOSYL COMPOUNDS;

EID: 66249135684     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3605     Document Type: Article

References (48)

1. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A 2006;103:18238-18242
2. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res 2008;68:3551-7; discussion 7.
3. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983;4:579-594 (Pubitemid 14243323)
4. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-1671
5. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459-476 (Pubitemid 39331277)
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. (Pubitemid 33741879)
7. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-153 (Pubitemid 36070433)
8. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566-1572 (Pubitemid 23228264)
9. Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921-927
10. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-2515 (Pubitemid 29269089)
11. Chen G, Wang X, Zhang S, et al. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 2005;63:395-406. (Pubitemid 40664351)
12. Hyytinen ER, Haapala K, Thompson J, et al. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 2002;82:1591-1598 (Pubitemid 35332918)
13. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-285 (Pubitemid 26074615)
14. Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994;54:2861-2864 (Pubitemid 24187763)
15. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 2004;23:527-533
16. Han G, Foster BA, Mistry S, et al. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 2001;276:11204-11213 (Pubitemid 38089305)
17. O'Mahony OA, Steinkamp MP, Albertelli MA, Brogley M, Rehman M, Robins D. Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. Mol Cancer Res 2008;6:1691-1701
18. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-9216 (Pubitemid 39665537)
19. Hofer MD, Kuefer R, Huang W, et al. Prognostic factors in lymph node-positive prostate cancer. Urology 2006;67:1016-1021 (Pubitemid 43956399)
20. Lim J, Ghadessy FJ, Abdullah AA, Pinsky L, Trifiro M, Yong EL. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2). Mol Endocrinol 2000;14:1187-1197
21. Perez-Stable CM, Pozas A, Roos BA. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol Cell Endocrinol 2000;167:43-53.
22. Robins DM. Androgen receptor and molecular mechanisms of male-specific gene expression. Novartis Found Symp 2005;268:42-52; discussion 3-6, 96-99
23. Inohara N, Koseki T, Lin J, et al. An induced proximity model for NF-κB activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 2000;275:27823-27831
24. Arezi B, Hogrefe HH. Escherichia coli DNA polymerase III epsilon subunit increases Moloney murine leukemia virus reverse transcriptase fidelity and accuracy of RT-PCR procedures. Anal Biochem 2007;360:84-91.
25. Riva A, Kohane IS. A SNP-centric database for the investigation of the human genome. BMC Bioinformatics 2004;5:33. (Pubitemid 38751302)
26. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541-1550 (Pubitemid 24034236)
27. Rees I, Lee S, Kim H, Tsai FT. The E3 ubiquitin ligase CHIP binds the androgen receptor in a phosphorylation-dependent manner. Biochim Biophys Acta 2006;1764:1073-1079 (Pubitemid 43912535)
28. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-540
29. Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997;3:1383-1388 (Pubitemid 27362400)
30. Bruggenwirth HT, Boehmer AL, Ramnarain S, et al. Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. Am J Hum Genet 1997;61:1067-1077 (Pubitemid 27492314)
31. Jagla M, Feve M, Kessler P, et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 2007;148:4334-4343 (Pubitemid 47295699)
32. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Janne OA. Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 1996;271:24151-24156 (Pubitemid 26327398)
33. Shen HC, Coetzee GA. The androgen receptor: unlocking the secrets of its unique transactivation domain. Vitam Horm 2005;71:301-319
34. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000;9:267-274 (Pubitemid 30052750)
35. Han G, Buchanan G, Ittmann M, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A 2005;102:1151-1156 (Pubitemid 40170741)
36. Robins DM. Multiple mechanisms of male-specific gene expression: lessons from the mouse sex-limited protein (Slp) gene. Prog Nucleic Acid Res Mol Biol 2004;78:1-36. (Pubitemid 39752477)
37. He B, Bai S, Hnat AT, et al. An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem 2004;279:30643-30653 (Pubitemid 38937996)
38. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 2002;277:36570-36576
39. Culig Z, Stober J, Gast A, et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect Prev 1996;20:68-75. (Pubitemid 2627098)
40. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005;280:37747-37754 (Pubitemid 41642384)
41. Yoshida T, Kinoshita H, Segawa T, et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65:9611-9616 (Pubitemid 41541433)
42. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
43. Dehm SM, Regan KM, Schmidt LJ, Tindall DJ. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res 2007;67:10067-10077 (Pubitemid 47621258)
44. Chandra S, Shao J, Li JX, Li M, Longo FM, Diamond MI. A common motif targets huntingtin and the androgen receptor to the proteasome. J Biol Chem 2008;283:23950-23955
45. Haapala K, Kuukasjarvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 2007;38:474-478 (Pubitemid 46237655)
46. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39 (Pubitemid 38524696)
47. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273-1281 (Pubitemid 32708680)
48. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008;68:3584-3590